Kornimate/medical-research-clean huggingface dataset:
mobile application in the management of mild to moderate postpartum depression (ppd)

Conditions: Post-partum Depression

Summary: primary objective: evaluate the user experience with the stella (tm) app for the management of postpartum depression in an observed population for 8 calendar weeks.

women between 18 and 50 years of age who have had a live birth within 4 months prior to study start date and have a diagnosis of mild to moderate ppd. a total of 65 women residing in the state of new york, new jersey and connecticut will be recruited to participate in the study. patient reported outcomes of mild to moderate depression (using epds) will be verified by a behavioral health therapist using the hamilton depression rating scale (ham-d).

Eligibility criteria:
inclusion criteria: 1. participants residing in the states of new york, new jersey or connecticut and must be able to read, write, and speak english, and provide written informed consent prior to enrollment 2. participants must be between 18 and 50 years of age 3. participants must have given live birth within the 4 months prior to the start of study 4. participants diagnosed with mild to moderate postpartum depression (as assessed by a clinician upon enrollment) and have scored between 9 and 21 on the edinburgh postnatal depression scale (epds) during screening 5. participants must answer "0/never" or "1/hardly ever" to the self-harm question on epds (question #10) 6. participants must be willing to use a mobile app and own an ios enabled mobile phone 7. participants must have wireless internet connectivity in the home and be willing to connect devices to their home wi-fi network. exclusion criteria: 1. participants who do not reside in the states of new york, new jersey or connecticut 2. participants who are not able to read, write, and speak english, and provide written informed consent prior to enrollment 3. participants less than 18 and more than 50 years of age 4. participants who have not given birth within the 4 months prior to the start of study or did not have a live birth in the last 4 months 5. participants who have not been diagnosed with postpartum depression upon clinical assessment or do not have a score of between 9 and 21 on the epds 6. participants with a positive (2 or 3) answer on the epds self-harm question (question #10) 7. participants with serious mental illnesses (smis), severe depression, or cognitive impairments

Keywords: post-partum depression, depression, anxiety, ppd
anovaos network powered patient registry

Conditions: Infectious Disease; Neoplasms; Diseases of the Blood and Blood-Forming Organs and Certain Disorders Involving the Immune Mechanism (D50-D89); Endocrine, Nutritional and Metabolic Diseases (E00-E89); Mental and Behavioural Disorders; Diseases of the Nervous System; Diseases of the Eye and Adnexa; Diseases of the Ear and Mastoid Process; Diseases of the Circulatory System; Diseases of the Respiratory System; Diseases of the Digestive System; Diseases of the Skin and Subcutaneous Tissue; Diseases of the Musculoskeletal System and Connective Tissue; Diseases of the Genitourinary System; Pregnancy, Childbirth and the Puerperium; Certain Conditions Originating in the Perinatal Period; Congenital Malformations, Deformations and Chromosomal Abnormalities (Q00-Q99); Symptoms, Signs and Abnormal Clinical and Laboratory Findings, Not Elsewhere Classified; Injury, Poisoning and Certain Other Consequences of External Causes; External Causes of Morbidity and Mortality; Factors Influencing Health Status and Contact With Health Services

Summary: the objective of this study is the development, implementation and management of a registry of patient data that captures clinically meaningful, real-world, data on the diagnosis, nature, course of infection, treatment(s) and outcomes in patients with complex disease globally.

the anovaos™ network powered patient registry may be used to inform the development and conduct of clinical trials and observational studies designed to better understand, prevent, diagnose, treat, ameliorate or cure disease. the anovaos™ network powered patient registry may additionally be used to expedite identification and recruitment of participants for clinical trials of promising therapeutics and observational studies.

Eligibility criteria:
inclusion criteria: * 18 years old or older; * confirmed positive diagnosis of disease, condition or disorder. this will be self-reported or reported by the patient's provider, advocacy group or other patient representative; * laboratory or other independent means of confirmation is not required but may be confirmed in clinical trials; * able to understand and willing to sign the informed consent document; or whose legal representative has given consent to participate in the research per state and federal requirements; * willing and able to complete the registry questions or have the instrument(s) completed by an informed proxy; * anticipated additional follow up with the registry once per year. exclusion criteria: * subjects who do not meet the inclusion criteria for the study; * subjects who are unable to understand the protocol or unable to provide legally effective informed consent

Keywords: infectious disease, cancer/oncology, neurology, immunology, cardiology
crtd responders optimization

Conditions: Heart Failure; Heart Failure With Reduced Ejection Fraction; Cardiac Death

Summary: suboptimal optimization of atrio-ventricular (av) and inter-ventricular (vv) timings could affect the clinical response of crtd in t2dm patients. thus, authors hypothesize that automatic sensor guided crtd optimization could ameliorate clinical outcomes in patients with t2dm. however, authors will evaluate the effects of cardiac resynchronization therapy (crtd) in patients with type 2 diabetes mellitus (t2dm) optimized via automatic vs. echocardiographic guided approach.authors will conduct a prospective, multicenter study to recruit, from october 2016 to june 2019, patients with t2dm and heart failure (hf) candidate to receive a crtd. after crtd the patients will be optimized via automatic vs. echocardiographic guided approach.


Eligibility criteria:
inclusion criteria: * heart failure with reduced cardiac pump, nyha class ii/iii, indication to receive a crtd. exclusion criteria: * nyha class iv, previous crtd implantation, neoplastic disease, inflammatory chronic disease.
clinical evaluation of a new dual-cure universal adhesive

Conditions: Class I Dental Restorations; Class II Dental Restorations; Insufficient Dental Restoration; Caries, Dental

Summary: the overall aim of this study is to evaluate the clinical performance and safety of the new dental dual-cure adhesive for luting indirect ceramic restorations (inlays and onlays). the primary aim is to determine the rate of postoperative hypersensitivity occurrence after using the new adhesive for the placement of indirect restorations. the secondary objective of this study is to assess the long-term clinical performance of the new adhesive in terms of marginal quality, retention/fracture rate of the ceramic restorations, and vitality/fracture rate of the restored teeth.


Eligibility criteria:
inclusion criteria: * age: 18-65 years * informed consent signed and understood by the subject * indication for indirect restorations (inlay, onlay) in molar or premolar * the occlusal area of the restoration must cover at least 1/3 of the occlusal area of the tooth. * visual analogue scale (vas)\&lt;4 (0=no pain, 10=maximum conceivable pain) * max. 2 restorations per participant in different quadrants. * vital tooth * healthy periodontium, no active periodontitis * contact with adjacent teeth (at least at one side) and opposing teeth present with at least one contact point. * sufficient language skills exclusion criteria: * insufficient isolation * participants with a proven allergy to one of the ingredients of the materials used * participants with proven allergy to local anaesthetics * high caries activity/ poor oral hygiene * participants with severe systemic diseases * pregnancy * tooth with irreversible pulpitis * indication for direct pulp capping * bleaching of teeth within the last 14 days * usage of peroxide-based disinfectants within the last 14 days
effects of bolus surfactant therapy on peripheral perfusion index and tissue carbon monoxide

Conditions: Respiratory Distress Syndrome

Summary: exogenous bolus surfactant administration may affect hemodynamic parameters and peripheral perfusion. surfactant therapy is commonly used for respiratory distress syndrome in premature infants, which is also associated with inflammation. there are different types and doses of surfactant preparations available. with the help of new generation monitors, changes in peripheral perfusion and transcutaneous co, a marker of inflammation, may be demonstrated.

preterm infants with severe respiratory distress syndrome (study group) were compared to preterm infants without respiratory distress syndrome(control group). infants in the study group were randomized to receive either poractantalfa or beractant. perfusion index (pi) and transcutaneous co (tco) values were measured before (tp) and 0 (t0), 5 (t5), 30 (t30), 60 (t60), 360 (t360) minutes after surfactant administration in the first six hours of life.

Eligibility criteria:
inclusion criteria: * gestational age between 26 and 36 weeks * intubated for respiratory distress syndrome exclusion criteria: * cardiac defects, * hemodynamically significant patent ductusarteriosus, * congenital pneumonia, * early sepsis * unstable infants in need of inotropic support.

Keywords: newborn perfusion index pulsatility index respiratory distress syndrome surfactant transcutaneous carbon monoxide
collaborative care coordination program for alzheimer's disease and related dementias

Conditions: Alzheimer's Disease and Related Dementias (ADRD)

Summary: this is a randomized, pragmatic clinical trial to evaluate the effectiveness of a collaborative care-coordination program embedded in a health plan for people living with alzheimer's disease and related dementias (adrd) and their care partners versus usual care. the study population will include community-dwelling medicare advantage members living with adrd and their care partners. outcomes will be healthcare utilization outcomes of individuals with adrd and include emergency department visits, outpatient visits, avoidable emergency department visits, and admission to long-term care facilities.


Eligibility criteria:
community-dwelling tufts health plan medicare advantage members with adrd and their caregivers will be selected to participate in the trial based on the following inclusion/exclusion criteria: inclusion criteria (for members with adrd) * member of tufts health plan medicare advantage plan * medical and pharmacy insurance coverage in at least the prior 12 months * have ≥1 icd-10-cm diagnosis code for adrd or dispensing for pharmacological treatment for adrd in the prior 12 months exclusion criteria (for members with adrd): * reside in a nursing home or skilled nursing facility * enrolled in a hospice program * receiving or have received the dementia care consultation program as part of the existing program at the time of enrollment inclusion criteria (for caregivers) * age 18 years or older * assume primary responsibility for members

Keywords: dementia informal caregiver care consultation care coordination
role of natural light in the prevention of delirium after cardiac surgery: a prospective observational study with historical control

Conditions: Intensive Care Unit Delirium; Postoperative Delirium; Cardiac Surgery

Summary: postoperative delirium is a common complication that usually occurs acutely within the first 24 hours after surgery and resolves within 72 hours; it is common in all medical areas and particularly affects patients over the age of 65 and those with pre-existing cognitive impairments. it is characterized by difficulty organizing and coordinating thoughts and by slowing down motor functions that are observed for a short period after surgery. the study will be an observational prospective study with historical control (pre/post-study) whose primary objective is to identify the incidence of postoperative delirium in patients undergoing cardiac surgery. the population will be adult patients undergoing cardiac surgery at our university hospital over a period of 12 months. the intervention will be exposure to totally artificial light (for patients hospitalized after the relocation of the department to its original location). the comparator will be exposure to natural light (for patients who will be hospitalized during our temporary transfer to an environment with natural lighting). the outcome will be the incidence of delirium, measured with the confusion assessment method-intensive care unit (cam-icu) scale; episodes of agitation requiring sedative drugs; time elapsed before onset of delirium. the study will last 12 months.


Eligibility criteria:
inclusion criteria: * planned cardiac surgery * planned icu admission after surgery exclusion criteria: * cardiac surgery with total suspension of cerebral perfusion * patient with diagnosed dementia or major depressive disorder * patient unable to perform cam-icu evaluation * emergent surgery * patient in icu before surgery

Keywords: cardiac surgery postoperative delirium natural light
artesunate vaginal inserts for the treatment of cervical intraepithelial neoplasia (cin2/3)

Conditions: CIN 2/3; HPV Infection; Pre-Cancerous Dysplasia; Cervical Dysplasia; HPV Related Disease

Summary: this is a phase ii double blind, placebo-controlled, randomized study of artesunate vaginal inserts for the treatment of women who have cervical high grade intraepithelial neoplasia (cin2/3).

eligible participants in this study are randomized 2:1 to receive either artesunate or placebo vaginal inserts for the treatment of cin2/3. both groups receive three 5-day cycles of the respective drug, at weeks 0, 2, and 4. dosing visits can be done as telehealth visits (medication is mailed to the patient's home). participants are followed after receiving artesunate at weeks 6, 17, and 40. all participants undergo a leep procedure at week 17. primary objective: to evaluate the histopathologic response to three 5-day cycles of artesunate vaginal inserts in adult females with biopsy-proven hpv-associated cin 2/3. secondary objectives: * to evaluate the safety of artesunate vaginal inserts for the treatment of cin2/3 * to evaluate the viral clearance after three 5-day cycles of artesunate vaginal inserts in adult females with biopsy-proven hpv-associated cin 2/3. * to evaluate viral clearance after three 5-day cycles of artesunate and the leep procedure

Eligibility criteria:
inclusion criteria: * adult females age ≥ 25 years * capable of informed consent * any hpv genotype detectable by dna test/hpv genotyping * colposcopically-directed, histologically confirmed tissue diagnosis of cervical high grade squamous intraepithelial lesions (cin2, cin3, or cin2/3) * women of childbearing potential agree to use birth control through week17 of the study. * weight ≥ 50kg exclusion criteria: * pregnant and nursing women * active autoimmune disease * taking immunosuppressive medication * hiv seropositivity * immunocompromised subjects * evidence of concurrent cervical adenocarcinoma in situ * concurrent malignancy except for nonmelanoma skin lesions, because treatment for other cancers have systemic effects

Keywords: treatment study cancer prevention non-surgical hpv related disease cin topical treatment vaginal inserts artesunate artemisinin non-invasive high risk hpv vaginal suppository
polyethylene glycol for childhood constipation

Conditions: Constipation

Summary: background: aim: clinical evaluation of the effectiveness of two different polyethylene glycol doses for the maintenance treatment of functional constipation in children. study design: randomized, open-label trial. randomized, double-blind, placebo controlled trial.

children will be randomly assigned into 2 groups receiving polyethylene glycol 4000 (forlax) with an initial dose of either 0.3g/kg, or 0.7 g / kg. in case of ineffectiveness the dose of medication will be increased every two weeks with 0.2 g/kg. the indication for the increase in dose will be less than 3 bowel movements per week. for children with diarrhea defined as more than 3 loose stools for minimum 2 days or/and severe abdominal pain the macrogol dose of will be reduced every two weeks by 0.2 g/kg. the intervention will last 6 weeks.

Eligibility criteria:
inclusion criteria: * age 1 - 18 age * functional constipation according to the rome iii criteria * consent of parents or guardians of the child to participate and study exclusion criteria: * organic cause constipation (including surgeries within the lower gi tract)

Keywords: constipation children polyethylene glycol
study comparing tigecycline to imipenem/cilastatin in complicated intra-abdominal infections in hospitalized subjects

Conditions: Gram-Positive Bacterial Infections; Cross Infection

Summary: purpose: to provide a mechanism for the emergency use of tigecycline in the appropriate clinical situations.


Eligibility criteria:
inclusion criteria: * male or female subjects, ≥ 8 years of age and a weight of ≥ 35 kilograms * subjects with selected culture-positive infections caused by a multiple antibiotic-resistant pathogen presumed to be susceptible to tigecycline * subjects who have failed or are intolerant of other available appropriate antibiotic therapies or whose pathogens are resistant to other available antibiotics exclusion criteria: * subjects who are moribund with an expected survival of less than 2 weeks. * subjects who have been designated as "do not resuscitate", unless it is anticipated within a reasonable degree of medical certainty that they can achieve benefit from potentially curative antibiotic therapy * known or suspected hypersensitivity to tigecycline, tetracyclines, or other compounds related to this class of antibacterial agents

Keywords: bacterial infections
clinical study and gene mutation analysis of adrenoleukodystrophy in taiwanese children

Conditions: Adrenoleukodystrophy

Summary: study the clinical manifestations and gene mutation of taiwanese ald patients


Eligibility criteria:
inclusion criteria: * x-ald patients and family exclusion criteria: -

Keywords: search as text words in annotation & scope note
equity in prevention and progression of hypertension by addressing barriers to nutrition and physical activity

Conditions: Prehypertension; Hypertension; Blood Pressure

Summary: the goal of this study is to test an intervention to prevent high blood pressure among rural, black adults living in alabama. black adults in this region have one of the highest rates of high blood pressure in the us. eating fruits and vegetables and exercising daily lowers the chance of getting high blood pressure. many problems get in the way of eating a healthy diet and exercising like a lack of grocery stores with fresh foods, few gyms, little money, lack of transportation, and limited support for keeping healthy habits. one place where many black adults in rural alabama meet weekly and feel supported is their church. the investigators will connect with 30 churches in rural alabama. the investigators plan to hold health fairs to find 12 black adults from each church with blood pressure that is higher than normal but not high enough to need blood pressure lowering medications. the investigators will randomly select 15 churches to get group health education and tablets to access online cooking shows and exercise classes. adults in the other 15 churches will get support from a health coach over the telephone to help set and meet diet and physical activity goals as well as the group health education and tablets to access online cooking shows and exercise classes. in this study, the investigators will ask church members to sign up to be a health coach. these 15 churches will also get money to help bring healthy foods and/or physical activity opportunities to their communities. the investigative team will train 2 to 3 of their church members to learn how to coach others to eat more healthy food and be more physically active. this study answers two questions. 1) will this intervention designed to reduce barriers to a healthy lifestyle lower blood pressure among rural, black adults? 2) can churches and participants complete the whole two-year study, and can the intervention be used in other communities in a cost-effective way to improve blood pressure? this project will add to the health equity mission of the american heart association by finding out if an intervention using health coaches lowers blood pressure among rural black adults.


Eligibility criteria:
inclusion criteria: * self-identify as black/african american * mean systolic blood pressure 120-139mmhg or diastolic blood pressure 80-89mmhg exclusion criteria: 1. mean systolic blood pressure greater than or equal to140 mm hg, or mean diastolic blood pressure greater than or equal to 90 mm hg 2. currently taking antihypertensive medication 3. self-reported history of hypertension outside of pregnancy 4. known pregnancy 5. self-reported history of cardiovascular disease 6. age ≥65 years or self-reported history of chronic kidney disease, or diabetes, if systolic blood pressure ≥ 130 mm hg or diastolic blood pressure ≥ 80 7. planning to move out of the county within the next 18 months 8. not having a cellular phone or landline 9. inability to speak english
sexual functioning after primary treatment of ovarian cancer

Conditions: Ovarian Cancer; Sexual Dysfunction

Summary: the purpose of this study is to help us learn more about sexual problems after treatment for ovarian cancer. at this time, we do not know how many women have sexual problems after they are treated for ovarian cancer. how common are sexual problems after treatment for ovarian cancer? * what factors make women more likely to have sexual problems after treatment for ovarian cancer? * what happens to sexual functioning over the first 12 months after treatment? ie. does it get better or worse? • does referral to a specialized sexual health clinic help?


Eligibility criteria:
inclusion criteria: * women with any stage of invasive epithelial ovarian cancer who have completed frontline therapy within the past 6 months * women must have no clinical evidence of disease * at least 18 years of age * english speaking * able to participate in the informed consent process * women who present to sexual health clinic for the first time and meet all other eligibility criteria are eligible. their fsfi scores will be used to determine the primary endpoint of prevalence of sexual dysfunction. if they score over 26 on the fsfi, they may still elect to be followed at the shc. exclusion criteria: * active secondary cancer requiring cytotoxic chemotherapy at the time enrollment * evidence of recurrent/persistent disease by elevated ca125, findings on imaging (ct, pet scan etc) or physical examination * women with borderline (low malignant potential) ovarian cancers * women who are already in active evaluation and/or follow-up at the sexual health clinic * women with a history of prior whole pelvic radiation

Keywords: sexual dysfunction